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ABSTRACT 
Background 
The increasing worldwide prevalence of dementia is a major public health concern. Findings from 
some epidemiological studies suggest that diet and nutrition may be important modifiable risk 
factors for development of dementia. 
 
Objective 
To systematically evaluate the strength of the available evidence of an association of dietary 
factors with dementia including Alzheimer’s disease. 
 
Methods 
We systematically searched relevant publication databases and hand-searched bibliographies up 
to end July 2007. We included prospective cohort studies which evaluated the association of 
nutrient levels with the risk of developing dementia, and randomized intervention studies examining 
the treatment effect of nutrient supplementation on cognitive function. 
 
Results 
One hundred and sixty studies comprising ninety one prospective cohort studies and sixty nine 
intervention studies met the pre-specified inclusion criteria. Of these, thirty-three studies (19 cohort 
and 14 randomised controlled trials) investigated the effects of folate, B-vitamins and levels of 
homocysteine (a biomarker modifiable through B-vitamin supplementation) or fish/fatty acids and 
are the focus of the present report.  Some observational cohort studies indicated that higher dietary 
intake or serum levels of folate and fatty acid/fish and low serum levels of homocysteine were 
associated with a reduced risk of incident AD and dementia, while other studies reported no 
association. The results of intervention studies examining the effects of folic acid or fatty acid 
supplementation on cognitive function were inconsistent. 
 
Conclusions 
Available evidence is insufficient to draw definitive conclusions on the association of B vitamins 
and fatty acids with cognitive decline or dementia, and further long-term trials are required. 
 
Key words 
Dementia, Alzheimer’s disease, nutrition, Vitamin B, folate, fatty acids
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INTRODUCTION 
Alzheimer’s disease (AD) is the leading cause of dementia in later life and manifests as a 
progressive, degenerative brain disorder resulting in cognitive and behavioral decline and 
functional and physical dependency. The prevalence of severe cognitive impairment is projected to 
quadruple from current levels to 81 million worldwide by 2040 [1], and treatment of dementia 
imposes a significant burden on patients, caregivers and healthcare systems worldwide [2, 3]. AD 
is a heterogeneous condition at the genetic, neurobiological and clinical levels and no specific 
marker has been identified that qualitatively distinguishes AD from “normal” aging processes.  
 
At present, pharmacological therapies are not able to halt progression of dementia and only 
produce minimal symptomatic cognitive improvements for some patients [4-6]. Consequently there 
is an increasing interest in efforts to identify modifiable risk factors that may delay or prevent the 
risk of cognitive decline or dementia. These efforts recognize that many factors can promote brain 
health including maintenance of cognitive and social activity as well as physical exercise and 
healthy dietary practices [7-9].  
 
Nutritional intake can directly influence the availability of nutrients to the brain. Specific dietary 
nutrients may be used for membrane and synapse formation and neurotransmitter production [10]. 
There is increasing evidence that nutrients stimulate neural plasticity and ameliorate 
neurodegenerative processes in animal models [10]. Diet and nutrition may be important 
modifiable risk factors in the cause and prevention of cognitive decline and functional impairment 
[10-14]. The development of dementia may in part be a consequence of exposure to, or low intake 
of, particular nutrients over several decades, beginning in middle age or late adult life. 
 
The aim of this systematic review was to determine the strength of the available evidence that 
serum nutrient levels, dietary consumption or nutritional supplementation with nutrients were 
associated with the primary prevention or treatment of dementia. Our systematic search included a 
large range of nutrients; in this review we report on folate (either as folate in food or serum or as 
folic acid dietary supplements) with or without other B-group vitamins, serum homocysteine 
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concentration, polyunsaturated fatty acids [PUFA] and fish as these nutrient/food groups have 
been highlighted as potentially important in previous reviews on nutrition and cognitive function 
[12-16]. 
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MATERIALS AND METHODS 
Research Design and Methods 
The present report forms part of the findings of a large systematic search that assessed the 
strength of evidence linking a large number of nutrients with the treatment and prevention of 
dementia and AD [17]. The review has been reported according to the recent Preferred Reporting 
Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines [18]. 
Identification and retrieval of studies 
Potentially relevant studies were identified by searching the following electronic databases: 
PubMed, Embase and Cochrane Library, accessed July 2007. Search terms used included both 
Medical Subject Headings (MeSH) and free text terms. Neurocognitive search terms included 
“Alzheimer’s disease”, “dementia”, “cognitive decline” and “cognitive impairment”. Nutrient search 
terms included the common and chemical names for the dietary factors of interest. The 
neurocognitive and nutrient search terms were combined with a search strategy for identifying 
randomised controlled trials (RCTs), non-controlled intervention studies and prospective cohort 
studies (see Web Appendix 1 for full list of search terms). Bibliographies of identified relevant 
publications and previously published systematic and Cochrane review articles were hand-
searched for further references. 
 
Study selection criteria, data extraction and outcome measures 
Studies were eligible for inclusion if they were reports of randomized or non-randomized clinical 
trials or prospective cohort studies, where cognitive function was measured at both baseline and 
follow up. Case-control studies, cross-sectional studies or studies that provided only cross-
sectional correlation data were excluded from the present review due to the various sources of bias 
in these study designs. In addition to selection bias, case-control studies are susceptible to recall 
bias, which may occur when trying to ascertain past eating habits [19]. Cross sectional studies only 
measure association not causation [20]. Studies examining the effects of both single and multi-
nutrient status or supplementation were included in the review. No other restrictions were placed 
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on studies with regard to year of publication or language of publication (providing an English 
abstract was available). 
 
Study participants were healthy older people or people with cognitive impairment/decline or any 
type of dementia (including vascular dementia and AD), regardless of nutritional status. In these 
studies, dementia or AD diagnosis was generally confirmed using commonly accepted criteria such 
as those of the International Classification of Diseases (ICD-10) [21], the Diagnostic and Statistical 
Manual of Mental Disorders (DSM) [22] and the National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzheimer’s disease and Related Disorders 
Association (NINCDS-ADRDA) [23]. Mild cognitive impairment (MCI) was generally diagnosed 
using clinical criteria [24]. Cognitive function was assessed using a large number of different 
psychometric tests. 
 
This systematic review reports on the following nutrition-related exposures: single nutrients 
(folate/folic acid, other B-group vitamins, fatty acids), simple nutrient combinations (folic acid with 
other B-group vitamins), levels of homocysteine, and fish consumption (dietary source of the n-3 
polyunsaturated fatty acids, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)). 
These nutrient groups were specifically selected as they have been highlighted as potentially 
important in previous reviews [12-16]. The relevant outcome measures in this review were incident 
dementia or AD in cohort studies, and change in cognitive performance in intervention studies. 
Studies focusing on MCI exceeded the scope of the present review. It is of note that, while a 
relatively large number of reports on the prevention or treatment of dementia/AD with vitamin B12 
were identified in the initial phase of the systematic review, the majority were excluded as they 
were case series/studies and were not a relevant study type for inclusion in the present review. 
 
Following the identification of potentially relevant studies based on their title and abstract, full 
articles were obtained and evaluated by one researcher. A second independent assessor verified 
inclusion/ exclusion decisions. Disputes as to eligibility were referred to the author panel. Study 
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data were extracted by one member of the study team (SAM) and checked by a second member 
(SH). 
 
Quality assessment 
The methodological quality of RCTs was assessed using Cochrane Collaboration guidelines on 
randomization (method of generation and concealment of allocation), masking of treatment 
allocation and loss to follow-up [25]. 
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RESULTS 
Overall search findings 
In total, 7,796 references were identified by the systematic literature search of which 7,543 were 
excluded on examination of their titles and abstracts.  The full reports of 253 publications were 
assessed and of these 110 papers were excluded (see Web Appendix 2). Hand searching 
indentified a further 17 references and in total 160 papers met the inclusion criteria (Figure 1). 
 
The present review is restricted to thirty-three studies that reported on folate, B-vitamins, 
homocysteine levels or fish/fatty acids. Results for other nutrients studied (antioxidants, dietary 
patterns, multivitamins) are not presented here. Of the 33 included papers, 19 were cohort studies 
including 11 on folate, other B-group vitamins and/or homocysteine [26-36] and eight on fish, DHA 
or EPA [37-44]. The remaining 14 were randomised controlled trials (RCTs) including ten on folic 
acid with or without other B-group vitamins [45-54], and four on mixed fatty acids [55-58]. 
 
Folate and other B-vitamins 
Ten cohort studies (Table 1) evaluated the association of folate and other B-vitamins in cognitively 
intact or impaired aging participants with incident AD or dementia over a 3–9 year follow-up period 
[26-28, 30-36]. Only one study considered folate only [31], nine included vitamin B-12 [26-28, 30, 
32-36] and four included vitamin B-6 [27, 30, 32, 35] in their assessment. Sample sizes ranged 
from 93 to 1405 participants. Three of the studies reported dietary intake (including supplement 
use) [27, 30, 32] and seven examined nutrient concentrations in blood samples [26, 28, 31, 33-36]. 
The incidence rates of AD or dementia were compared between individuals based on their folate 
and B-vitamin intake or their blood concentrations at enrollment into the study. Two out of the three 
studies which considered dietary intake reported a significantly decreased risk of developing 
incident AD with increased folate consumption [27, 30], one of which also observed the same 
association with vitamin B-6 consumption [27]. There was no association between dietary vitamin 
B12 consumption and incident AD or dementia [27, 30, 32].  
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One study reporting serum folate found that low folate concentrations increased the risk of 
developing dementia and AD [33], whilst a second reported an increased risk of conversion from 
mild cognitive impairment to dementia for individuals with low serum folate [34]. The remaining five 
studies reported no association between blood folate levels at enrollment and the risk of 
developing AD or dementia [26, 28, 31, 35, 36]. One study reported an increased risk of cognitive 
impairment (including dementia and cognitively impaired but not demented individuals) with 
increased levels of plasma vitamin B-12 [28]; the remaining five studies found no association 
between vitamin B-12 and risk of dementia or AD [26, 33-36], although one of these did report a 
combined effect of low serum vitamin B-12 together with low folate and increased risk of AD and 
dementia [36]. 
 
Four RCTs (Table 2) investigated the effect of folic acid supplementation alone, on cognitive 
function [45, 46, 48, 52]. The method used for randomization of participants was adequately 
reported in two studies [46, 52] and unclear in the remaining studies [45, 48]. Study groups were 
comparable at baseline and masking was adequately addressed in all studies. Three of the studies 
reported that folic acid supplementation resulted in a significant improvement in memory and 
cognitive function for some of the outcomes studied [45, 46, 48], although one also reported a 
decline in one cognitive domain [45]. 
 
A further six RCTs (Table 2) examined the effect of supplementation of folic acid in combination 
with other B-vitamins on cognitive function [47, 49-51, 53, 54]. The method used for randomization 
was adequate in four studies, [49, 50, 53, 54] unclear in one study [51] and inadequate in the 
remaining study [47]. The method used for masking was adequate in three [50, 53, 54] and unclear 
in three studies [47, 49, 51]. Study groups were comparable at baseline in five of six studies [47, 
49, 50, 53, 54] and not reported in the remaining study [51]. None of the trials reported increased 
cognitive performance following supplementation with folic acid in combination with other B-
vitamins and three trials reported a trend for increased performance or slower decline in the 
placebo compared to vitamin groups [47, 49, 50].  
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Homocysteine 
Five cohort studies (Table 1) reported data on the relationship between levels of serum 
homocysteine and development of incident dementia and/or AD [26, 28, 29, 33, 35]. Four studies 
found a positive association between blood concentrations of homocysteine and incidence of 
cognitive impairment [26, 28, 33, 35], although in one the association was only apparent in the 
younger age group (mean age 60y) [26].  
 
Fish and Fatty acids
Eight cohort studies (Table 3) examined the effects of n-3 fatty acids on the incidence of dementia 
and AD [37-44], seven of which assessed dietary intake of fish and/or general PUFAs [37, 39-44], 
one study also assessed serum concentrations of DHA [41] and a final study reported only serum 
DHA, EPA and n-3 PUFA [38]. One study reported a marginal reduced risk of dementia and AD 
with increased fish consumption [42], and a second study reported a reduced risk of AD with 
increased total n-3 fatty acids, DHA and fish consumption [40]. The remaining dietary studies 
reported no association between n-3 fatty acid intake and risk of dementia and/or AD with the 
exception of a reduced risk of dementia associated with moderate PUFA intake from spreads 
reported by one study [44].  
 
Of the two studies investigating plasma fatty acids, one reported a reduced risk of dementia, but 
not AD, with higher compared to lower plasma DHA [41], while the second reported that individuals 
with dementia had higher concentrations of DHA and other n-3 PUFAs than individuals who did not 
develop the condition [38].  
 
Four RCTs (Table 4) examined the effect of mixed fatty acid supplementation on cognitive 
functioning [55-58]. The method of randomization employed was adequate in all studies and 
masking was either adequate [55, 58] or not clearly reported [56, 57]. These studies are 
characterized by a high level of inter-study variation in the nature of the intervention and study 
duration (4 weeks to 1 year). Only one study [56], which enrolled a small number of participants 
(n=20) and was not placebo-controlled, reported an improvement in cognitive measures while a 
second study reported improvements in quality of life following treatment [58]. It should be noted 
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however that in neither of these trials was the statistical analysis of the treatment effect clearly 
reported. There was no effect of fatty acid supplementation on cognitive function tests in the two 
remaining trials [55, 57].
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DISCUSSION 
The potential effect of dietary factors in both the prevention and treatment of dementia has become 
a topic of increasing interest. Reviews conducted to date have not identified good evidence for 
specific recommendation of particular dietary interventions [12-16, 59]. Despite this lack of 
evidence some health providers continue to recommend dietary supplements which may not confer 
additional benefits to an adequate diet [60], and individuals who perceive themselves to be at 
increased risk of dementia frequently seek nutritional therapy [61]. 
 
This systematic review identified some evidence from cohort studies that lower dietary intakes of 
folate or low levels of serum folate were associated with an increased risk of developing AD.  Trials 
of folic acid supplementation, either alone or in combination with other B-vitamins, had limited or no 
effect on measures of cognitive function. Older adults are likely to be at risk of low serum folate 
levels only in cases of low total energy intake [62], and over 50 countries currently implement 
mandatory fortification of flour with folic acid [63]. It should be noted that the relationship between 
dietary folate intake and serum folate levels is complex [64] and even where body stores of folate 
remain relatively constant, serum concentrations vary in line with changes in dietary folate intake 
and other physiological and health characteristics of study participants. The evidence from RCTs 
that provided folic acid supplementation in combination with other B vitamins is less supportive of a 
beneficial effect on cognitive function. The lack of any consistent beneficial effect on cognitive 
function of folic acid with or without vitamin B12 in healthy or cognitively impaired older participants 
has been confirmed in previous systematic reviews [16]. 
 
Three RCTs published subsequent to the searches performed for the present review do not 
provide support of the use of folic acid either individually or in combination with other B vitamins for 
the prevention of cognitive decline in older participants with or without diagnosed dementia [65-67]. 
This review identified some evidence that raised levels of homocysteine were associated with an 
increased incidence of AD and dementia. A recent review of case-control and cohort studies also 
reported that raised homocysteine levels were associated with an increase risk of AD but only 
included three of the five cohort studies in the current review [68] 
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Several recent reviews consider the role of fish consumption or fatty acids in the prevention of 
dementia or AD and come to the conclusion that the current evidence is in support of a protective 
effect of fish and n-3 fatty acid consumption [69-71]. Fish oils, especially DHA, may have 
neuroprotective actions [72], and some recent in vitro experiments [73] also suggest that DHA may 
play an important role in preventing late-onset AD.  In the current review, only two out of eight 
cohort studies that examined the effect of fish or DHA consumption reported reduced AD and 
dementia incidence in those participants with the highest intake levels. These findings have been 
confirmed in three recently published cohort studies [74-76], only one of which reported that higher 
plasma n-3 PUFA proportions predicted less decline in speed-related cognitive domains over three 
years follow-up [76]. In addition, two recently published RCTs provide no evidence of a benefit to 
cognitive function from supplementation with combinations of EPA and DHA among cognitively 
healthy older people [77, 78]  
 
This systematic review has several strengths. The use of a comprehensive search strategy 
(electronic databases in addition to selected conference proceedings) maximized the likelihood of 
identifying all potentially relevant publications. In addition, it is the most up-to-date systematic 
review of the published literature in this field and has a broad scope, focusing on both single and 
multiple nutrients and including both cohort and RCT studies. 
 
There are a number of factors which complicate interpretation of the results reported in studies 
included in this review.  First, included studies used a wide variety of cognitive function tests to 
measure different or overlapping domains of cognitive function [79]. Second, the degree to which 
cohort studies controlled for confounding or modifying factors differed. Third, the presence of 
subclinical dementia in the population at baseline may have differed between studies which could 
affect the dietary habits or participant response during the course of the study. Fourth the 
robustness of the dietary data is dependent on the use of a validated dietary assessment 
instrument to collect data during the study. Fifth, the time from exposure to a dietary factor to 
outcome measurement is invariably short, contrasting with the fact that the degenerative process 
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often takes several years before a diagnosis is/can be made. Finally the number of incident cases 
of AD or dementia reported at follow up was small in some studies which may limit the power to 
detect any associations. We were unable to conduct meta-analyses of the included studies due to 
marked heterogeneity in study designs, an issue that has similarly hampered other systematic 
reviews in this field [80]. Results from the prospective cohort studies frequently conflicted with 
findings from intervention trials. This is not a novel finding [81, 82], but suggests that future cohort 
studies and RCTs would benefit from better standardization of protocols. 
 
Multi-nutrient approaches have been proposed [10] and are supported by some [83] but not all 
available trial data [84].  Trials are underway among participants with early [85] and late-stage AD 
[86]. In addition, multi-domain interventions encompassing nutritional, physical and cognitive 
training may offer a potential synergistic effect in preventing cognitive decline in susceptible 
populations [87].  High-quality trials with clearly defined, well validated outcomes of interest are 
required to allow firm conclusions regarding the effects of either single nutrients or combinations of 
nutrients on neurodegenerative disorders. In addition, there is now increasing evidence to support 
the collection of genetic information from study participants to investigate potentially important 
nutrient gene interactions.  Finally, future trials should be conducted in people with the earliest 
stages of cognitive impairment, since the window of opportunity for effective intervention from the 
onset of symptoms may be limited [88].  In conclusion, the available evidence base is currently 
insufficient to draw firm conclusions about the effects of individual dietary factors on the 
development or treatment of AD and dementia, and further large, well-designed RCTs of long 
duration need to be undertaken [89]. 
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Table 1. Summary of cohort studies relating homocysteine, folate and other B-vitamins to risk of incident AD and dementia. 
First 
author, 
year 
Study population N 
(loss to 
follow-up) 
Duration 
(mean 
follow-
up) 
Exposure Cognitive 
measure 
Statistical analysis Outcomes / major results 
Annerbo, 
2006 [26]  
Males and females 
Mean age: 65.4y 
Community-
dwelling (hospital-
recruited) 
Mild cognitive 
impairment (MCI) 
(defined by MMSE 
score 21-27 and 
clinical evaluation) 
93 
(retro-
spective 
cohort, no 
loss to 
follow-up 
stated) 
6 years Routine 
hospital  
measures of 
serum 
homocysteine, 
folate and 
vitamin B-12 
collected at 
admission 
AD diagnosis 
based on 
criteria of the 
DSM-IV and 
ICD-10. 
Independent t-test 
comparing risk factors 
(homocysteine, folate 
and vitamin B-12) 
between converters (to 
AD) and non-
converters. 
Logistic regression 
used to assess impact 
of homocysteine on 
AD conversion 
adjusted for MMSE, 
thyroid-stimulating 
hormone and age. 
32 cases of incident AD. 
Homocysteine levels higher for 
converters (18.4µmol/l) compared to non-
converters (16.8µmol/l) (P: 0.034).  
No significant difference in folate (19.0 vs 
16.4nmol/l) or vitamin B-12 (275 vs 
305pmol/l) between groups.  
No main effect of homocysteine in 
adjusted model but interaction with age: 
higher homocysteine in lower age group 
(mean: 60y) associated with increased 
odds of AD (adjusted OR: 1.29; 95% CI: 
1.03, 1.61) (OR at 65y: 1.09; 95%CI: 
0.99, 1.37) 
Corrada, 
2005 [27]1
Males and females  
>60y 
Community-
dwelling 
Free of AD at 
baseline 
 
579 
(37%: 
variables 
associated 
with loss to 
follow-up 
not 
reported) 
9.3y Folate, vitamin 
B-6 and B-12 
intake from 
foods and 
supplements 
assessed by 
7-day record 
Battery of 
neuro-
psychological 
tests.  
AD diagnosis 
based on 
criteria from 
NINCDS-
Cox regression model, 
comparing risk of AD 
by nutrient intake 
above or below RDA 
(reference: below 
RDA).  
Adjusted for: age, 
gender, education, 
57 cases of incident AD  
Higher intake of folate associated with 
decreased risk of AD (≥ RDA (median 
619.0 µg/d)  vs  <RDA (median 
250.9µg/d);  adjusted RR: 0.41; 95% CI: 
0.22, 0.76) 
Higher intake of vitamin B-6 associated 
with decreased risk of AD (≥ RDA 
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ADRDA, 
included 
participants 
with 
diagnosis 
‘consistent 
with AD’ 
total caloric intake (median 2.4mg/d) vs <RDA (median 
1.1mg/d); adjusted RR: 0.41; 95% CI: 
0.2, 0.84). 
No association between vitamin B-12 
intake and risk of AD (≥ RDA (median 
7.2µg/d) vs <RDA (median 2.0µg/d); 
adjusted RR: 0.6; 95%CI: 0.26, 1.36) 
Haan, 
2007 [28]2
Males and females 
≥ 60y 
Community-
dwelling 
Primarily Mexican 
American 
Free of dementia or 
CIND at baseline 
1405 
(21%: 
variables 
associated 
with loss to 
follow-up 
not 
reported) 
4.5y Plasma 
homocysteine 
and vitamin B-
12, red blood 
cell (RBC) 
folate.  
Battery of 
neuro-
psychological 
tests.  
Dementia 
defined by 
criteria of 
DSM-III, 
NINCDS or 
ADRDA. 
CIND defined 
by failing 
(<10%) a 
cognition test 
but not 
diagnosed as 
having 
dementia  
Proportional hazards 
models examining the 
association between 
exposures and 
combined incidence of 
all cause dementia and 
CIND (combined 
incidence termed 
‘cognitive impairment’). 
Adjusted for: age, 
education, sex and 
vitamin B-12 or 
homocysteine  
62 cases of incident all cause dementia 
and 55 cases of incident CIND. 
Higher homocysteine (mean level: 
10.78µmol/l) associated with increased 
risk of cognitive impairment (adjusted 
HR: 2.39; 95% CI: 1.11, 5.16). 
Higher vitamin B-12 (mean: 452.59pg/ml) 
associated with increased risk of 
cognitive impairment (adjusted HR: 1.07; 
95% CI: 1.02, 1.11).  
No association between RBC folate 
(mean: 504.69 ng/ml) and cognitive 
impairment (unadjusted HR: 0.85; 95% 
CI: 0.57, 1.24).  
Luchsinger 
2004 [29]3
Males and females 
≥ 65y (mean: 76.2) 
679 
(25%: more 
3206 
person-
Plasma 
homocysteine 
Battery of 
neuro-
Cox proportional 
hazard model 
101 cases of incident AD 
In adjusted analysis, no association 
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Community-
dwelling 
Free of AD and 
dementia at 
baseline 
likely to be 
white rather 
than 
Hispanic) 
years psychological 
tests.  
AD diagnosis 
based on 
criteria from 
NINCDS-
ADRDA. 
comparing risk of AD 
by quartile of plasma 
homocysteine 
(reference: lowest 
quartile). 
Adjusted for: age, sex, 
education, APOE- ε4 
and stroke. 
between plasma homocysteine (highest 
quartile (mean 27.4µmol/l) vs lowest 
quartile (mean 10.75µmol/l) and risk of 
AD (adjusted HR: 1.3; 95% CI: 0.8, 2.3). 
Luchsinger 
2007 [30]3
Males and females  
≥ 65y (mean: 75.8) 
Community-
dwelling 
Free of AD and 
dementia at 
baseline 
 
965 
(34%: more 
likely to be 
older) 
6.1y  
(SD 3.3) 
 
Folate, vitamin 
B-6 and 
vitamin B-12 
intake 
(adjusted for 
energy intake) 
from foods and 
supplements 
assessed by 
semi-
quantitative 
FFQ 
Battery of 
neuro-
psychological 
tests.  
AD diagnosis 
based on 
criteria from 
NINCDS-
ADRDA. 
Cox proportional 
hazard model 
comparing risk of AD 
by quartile of nutrient 
intake (reference: 
lowest quartile).   
Adjusted for: age, sex, 
ethnic group, 
education, APOE-ε4, 
history of diabetes, 
hypertension, current 
smoking, heart disease 
and stroke, and levels 
of Vitamin B6 and B12. 
192 cases of incident AD 
Higher intake of folate associated with 
decreased risk of AD (highest folate 
intake (> 487.9µg/d) vs lowest folate 
intake (≤ 292.9 µg/d); adjusted HR: 0.5; 
95% CI: 0.3, 0.9) 
No association between vitamin B-6 
intake and risk of AD (highest B-6 intake 
(>4.5mg/d) vs lowest B-6 intake 
(<2.3mg/d); adjusted HR: 1.3; 95%CI: 
0.7, 2.3) 
No association between vitamin B-12 
intake and risk of AD (highest B-12 
intake (>13.5µg/d) vs lowest B-12 intake 
(<3.5µg/d); adjusted HR: 1.1; 95% CI: 
0.7, 1.7). 
Maxwell, 
2002 [31]4
Males and females  
≥ 65y (mean: 80.1) 
Community 
226 
(57%: more 
likely to be 
5y Serum folate Screened 
using 3MS 
and clinical 
Logistic regression 
comparing odds of AD 
between quartiles of 
49 cases of incident AD. 
No association between baseline folate 
status and incident AD (lowest folate 
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dwelling and 
institutionalized 
participants 
Free from AD and 
dementia at 
baseline but with 
3MS score <78 
 
 
younger, 
less 
educated 
and 
community 
dwelling  
examination. 
Dementia 
diagnosis 
based on 
criteria from 
DSM-III. AD 
diagnosis 
based on 
criteria from 
NINCDS-
ADRDA. 
 
serum folate 
(reference: lowest 
quartile). 
Adjusted for age and 
sex 
quartile (median 11.3nmol/l) vs highest 
folate quartile (median 25.0nmol/l); 
adjusted OR: 2.17; 95% CI: 0.85, 5.53) 
Morris, 
2006 [32]5
 Males and females 
 ≥ 65y 
Community 
dwelling 
Free of AD, with 
range of good to 
poor cognitive 
performance at 
baseline 
 
 
1041 
(83%: 
variables 
associated 
with loss to 
follow-up 
not 
reported) 
median 
3.9y  
 
Folate, vitamin 
B-6 and 
vitamin B-12 
intake from 
foods and 
vitamin 
supplements 
assessed by 
FFQ  
Structured 
clinical 
evaluations. 
AD diagnosis 
based on 
criteria from 
NINCDS-
ADRDA. 
Logistic regression 
comparing the odds of 
incident AD for quintile 
of nutrient intake 
(reference: lowest 
quintile). 
Adjusted for: age, time 
period of observation, 
indicator variable for 
quintiles of nutrient 
intake sex, race, 
education, APOE-ε4, 
intake of vitamin E 
from food sources, 
frequency of 
161 cases of incident AD. 
No association between risk of 
developing AD and quintiles of total 
folate intake (highest folate intake 
(median 752.7 µg/d) vs lowest folate 
intake (median 202.8 µg/d); adjusted OR: 
1.6; 95% CI: 0.5, 5.2). 
No association between risk of 
developing AD and quintiles of total 
vitamin B-6 intake (highest B-6 intake 
(median 5.5mg/d) vs lowest B-6 intake 
(median 1.2mg/d); adjusted OR: 0.7; 
95% CI: 0.2, 2.4) 
No association between risk of 
developing AD and quintiles of total 
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participation in 
cognitive activities, 
total intake of niacin 
vitamin B-12 intake (highest B-12 intake 
(median 20.6µg/d) vs lowest intake 
(median 3.1µg/d); adjusted OR: 0.6; 
95%CI: 0.2, 1.6) 
Ravaglia, 
2005 [33]6
Males and females  
≥ 65y (mean: 73.6) 
Community 
dwelling  
Free of dementia at 
baseline 
816  
(13%: 
variables 
associated 
with loss to 
follow-up 
not 
reported) 
3.8y 
(SD: 0.8) 
Plasma 
homocysteine, 
serum folate 
and vitamin B-
12 
Italian 
version of 
MMSE [90] 
and Mental 
Deterioration 
Battery [91].  
Dementia 
diagnosis 
based on 
criteria from 
DSM-IV. 
AD diagnosis 
based on 
criteria from 
NINCDS-
ADRDA. 
Cox proportional 
hazard model 
comparing risk of 
dementia and AD for 
low (below median) 
compared to high 
serum folate and 
vitamin B-12 or for 
those with or without 
hyperhomocysteinemia 
Adjusted for: age, sex, 
education, APOE-ε4, 
stroke, serum 
creatinine, smoking 
status, diabetes, 
hypertension, 
cardiovascular disease 
and BMI. Additionally 
adjusted for 
homocysteine, folate 
or B-12 depending on 
outcome of interest. 
112 cases of incident all cause dementia 
(70 of which were AD) 
Hyperhomocysteinemia (homocysteine 
>15µmol/l) associated with increased risk 
of dementia and AD (adjusted HR for all 
cause dementia: 2.18; 95%CI: 1.37, 
3.48; adjusted HR for AD: 2.08; 95%CI: 
1.15, 3.79) 
Low folate associated with increased risk 
of dementia and AD (low folate (≤ 
11.8nmol/l)); adjusted HR for all cause 
dementia: 1.87; 95% CI: 1.21, 2.89; 
adjusted HR for AD: 1.98; 95% CI: 1.15, 
3.40). 
No association between serum B-12 and 
risk of dementia and AD  
(adjusted HR for all cause dementia: 
0.83; 95% CI: 0.56, 1.24; adjusted HR for 
AD: 0.66; 95% CI: 0.40, 1.09) 
Ravaglia, Males and females 165 2.8y Serum folate Battery of Cox proportional 48 cases of incident dementia (of which 
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2006 [34] >60y 
Community 
dwelling 
Mild cognitive 
impairment (MCI) 
classified by 
Petersen’s criteria 
[24] and the Italian 
version of MMSE 
[90] 
(13%: more 
likely to be 
older, 
female, 
lower 
MMSE 
score at 
baseline) 
(SD: 1.6) and vitamin B-
12 
neuro-
psychological 
tests.  
Dementia 
defined as ≥2 
cognitive 
domains 
severe 
enough to 
affect 
functional 
abilities 
hazards ratio for risk of 
conversion to all cause 
dementia from MCI for 
low (below 25th 
percentile) compared 
to high serum folate or 
vitamin B-12.  
Adjusted for: age, 
gender, education, 
high (≥ 26) MMSE, 
MCI subtype, diastolic 
BP, atrial fibrillation 
and BMI categories 
 
34 were AD). 
Low serum folate associated with 
increased risk of conversion to all cause 
dementia (low folate (≤10.4nmol/l); 
adjusted HR: 3.11; 95% CI: 1.49, 6.47). 
Serum vitamin B-12 not associated with 
risk of conversion to all cause dementia 
(low B-12 (≤ 217pmol/l); HR adjusted for 
age, gender and education only: 0.6; 
95% CI: 0.26, 1.39). 
Seshadri, 
2002 [35]7
Males and females 
Mean age: 76 (SD: 
6) 
Free of dementia at 
baseline 
1092 
(58%: 
variables 
associated 
with loss to 
follow-up 
not 
reported) 
Median: 
8y 
Plasma 
homocysteine, 
folate, vitamin 
B-12 and 
vitamin B-6 
Dementia 
diagnosis 
based on 
criteria of 
DSM-IV as 
well as a 
duration of 
symptoms >6 
months and 
a score of ≥ 
1 of severity 
on the 
Clinical 
Cox proportional 
hazards models to 
assess relationship 
between exposures 
and incidence of all  
cause dementia and 
AD. 
Adjusted for: age, sex, 
APOE genotype, 
history of stroke, 
smoking status, 
alcohol intake, 
diabetes mellitus, BMI, 
111 cases of incident dementia (of which 
83 were AD). 
Higher homocysteine (mean for men: 
13.1µmol/l; for women: 13.0µmol/l) 
associated with increased risk of 
dementia and AD (adjusted RR for all 
cause dementia: 1.4; 95% CI: 1.1, 1.9; 
adjusted RR for AD: 1.8; 95% CI: 1.3, 
2.5). 
Folate, vitamin B-12 and vitamin B-6 not 
associated with risk of dementia or AD 
(data not shown) 
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Dementia 
Rating scale. 
AD defined 
based on 
criteria from 
NINCDS-
ADRDA. 
systolic BP.  
Additionally adjusted 
for homocysteine, 
folate, B-12 or B-6 
depending on outcome 
of interest. 
Wang, 
2001 [36]8
Males and females 
>75y 
Community 
dwelling 
Free of dementia 
but cognitively 
impaired (MMSE 
score <24) 
370 
(0%) 
3y Serum folate 
and vitamin  
B-12 
Dementia 
diagnosis 
based on 
criteria from 
DSM-III, or 
from hospital 
records for 
those who 
had died (n: 
86) 
Cox proportional 
hazard model 
comparing risk of 
dementia and AD for 
low (deficient) 
compared to high 
serum folate or vitamin 
B-12. 
 Adjusted for: age, sex 
and education  
78 cases of incident dementia (of which 
60 were AD).  
Low serum folate (≤ 10nmol/l) was not 
associated with risk of dementia or AD. 
(adjusted RR for all cause dementia: 1.6; 
95% CI: 0.9, 2.9; adjusted RR for AD: 
1.7; 95% CI: 0.9, 3.2) Low serum B-12 (≤ 
150pmol/l) was not associated with risk 
of dementia or AD (adjusted RR for all 
cause dementia: 1.3; 95% CI: 0.7, 2.3; 
adjusted RR for AD: 1.6; 95% CI: 0.9, 
2.8). 
Combined low serum folate or low serum 
B-12 was associated with increased risk 
of dementia and AD (adjusted RR for all 
cause dementia: 1.8; 95% CI: 1.1, 2.8; 
adjusted RR for AD: 2.1; 95% CI: 1.2, 
3.5) 
3MS = Modified Mini-Mental State (3MS) examination [92]; 95% CI = 95% Confidence Interval; AD = Alzheimer’s Disease; BMI = Body Mass Index; BP = Blood 
Pressure; CIND = Cognitively Impaired but Not Demented; DSM-III/IV= Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition [93]/ 4th Edition [22]; FFQ = 
Food Frequency Questionnaire; HR = Hazard Ratio; ICD-10 = International Classification of Diseases, 10th Edition [21]; MMSE = Mini-Mental State Evaluation [94]; 
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NINCDS-ADRDA = National Institute of Neurological and Communicative Disorders and Stroke – Alzheimer’s Disease and Related Disorders Association [23]; OR = 
Odds Ratio; RDA = Reference Dietary Allowance according to US Institute of Medicine [95]; RR = Risk Ratio; SD = Standard Deviation 
1Baltimore Longitudinal Study of Aging (BLSA); 2 Sacramento Area Latino Study on Aging (SALSA); 3Washington Heights-Inwood Columbia Aging Project 
(WHICAP); 4Canadian Study of Health and Aging (CSHA); 5Chicago Health and Aging Project (CHAP); 6Conselice Study of Brain Aging (CSBA); 7The Framingham 
Heart Study; 8The Kungsholmen Project 
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Table 2. Summary of RCTs examining folic acid intervention (with or without B vitamins) on cognitive function. 
First 
author, 
year 
Study population N Intervention1 Duration Cognitive measure Outcome / main results 
Bryan, 
2002 [45] 
Women only 
Three age bands: 20-
30y; 45-55y and 65-92y 
Community-dwelling 
Non-smoking, not 
pregnant or lactating, 
no oral contraceptives 
or hormone 
replacement and no 
medication likely to 
affect mental 
performance or mood. 
  
211 4 trial arms: 
a. folate 
(750µg/d); 
b. vitamin B-12 
(15µg/d); 
c. vitamin B-6 
(75mg/d) 
d. placebo 
35 days Cognitive performance assessed at 
baseline and after treatment.  
Cognitive performance tests: speed of 
processing (boxes test, digit symbol-
coding and symbol search); working 
memory (digit span-backwards and 
letter-number sequencing); memory 
(Rey auditory-verbal learning test, recall 
of digit-symbol-coding and activity 
recall); executive function (neuro-
psychological test); verbal ability 
(vocabulary and spot-the-word).  
Statistical analysis of the intervention 
effect focused on the interaction 
between treatment x age x time of 
testing (pre and post intervention) 
Supplementation reduced verbal 
fluency performance (P: <0.05). 
When stratifying by age, 
supplementation improved Rey 
auditory-verbal learning test in older 
(65-92y) participants (P: <0.05). 
Durga, 
2007 [46] 
Males and females 
50-70y (mean: 60) 
Community-dwelling 
Excluded individuals 
with low (< 13µmol/l) or 
raised (> 26µmol/l) 
homocysteine  
818 800µg/ day folic 
acid vs placebo 
 
3 years Cognitive function assessed at baseline 
and after treatment. 
Cognitive tests from Maastricht Aging 
Study [96], characterizing following 
domains: memory; sensorimotor speed; 
complex speed; information processing 
speed and word fluency. 
Folic acid improved global cognitive 
function (average of 5 domains) (mean 
difference in cognitive change Z-score: 
0.05; 95% CI: 0.004, 0.096; P: 0.033). 
Domain-specific analysis: information 
processing speed declined in both 
groups but less in folic acid group 
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No B-vitamin 
supplements 
Test components: word learning test, 
concept shifting test, Stroop color-word 
test, verbal fluency test and letter digit 
substitution test 
(mean difference: 0.087; 95% CI: 
0.016, 0.158; P: 0.016).  
Memory improved in both groups with 
a bigger improvement in folic acid 
group (mean difference: 0.132; 95%CI: 
0.032, 0.233; P: 0.01). 
Sensorymotor speed declined in both 
groups but less in folic acid group 
(mean difference: 0.064; 95% CI: -
0.001, 0.129; P: 0.055) 
Eussen, 
2006 [47] 
Males and females 
≥ 70y (mean: 82) 
Community and 
Institutional-dwelling 
Mild vitamin B-12 
deficiency (serum B-12 
100-200pmol/l or 200-
300pmol/l plus 
methylmalonic acid  
≥ 0.32µmol/l and 
creatinine ≤ 120µmol/l) 
No vitamin B-12 or folic 
acid supplementation 
MMSE score ≥ 19 
162 3 trial arms:  
a. vitamin B-12 
(1mg/d);  
b. B-12 (1mg/d) + 
folic acid 
(400µg/d);  
c. placebo 
24 
weeks 
Cognitive function assessed at baseline 
and after treatment.  
Battery of neuopsychologic tests 
assessed sensorymotor speed, 
construction memory, executive 
function, attention and memory.  
MMSE also conducted 
No effect of vitamin B-12 alone or in 
combination with folic acid on cognitive 
function.  
Only memory domain showed 
significant difference between trial 
groups (time x treatment interaction: P: 
0.014), although each group improved, 
the greatest improvement was in the 
placebo group.  
Fioravanti, 
1997 [48] 
Males and females 
70-90y (mean: 80.2) 
Community-dwelling 
30 15mg folic acid/d vs 
placebo 
  
60 days Cognitive status assessed at baseline 
and after treatment.  
Cognitive function assessed by Randt 
Folic acid improved attention efficiency 
score (P <0.05). 
When taking into account baseline 
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Mild to moderate 
severity of cognitive 
decline (GDS) 
MMSE score 16-24 
Serum folate <3ng/ml 
 
Memory Test (RMT) [97].  
Test components: acquisition and recall; 
delayed recall; memory index; encoding 
factor; cognitive efficiency; attention 
efficiency 
folate status, folic acid improved 
acquisition and recall (P<0.007); 
delayed recall (P<0.007), memory 
index (P<0.002) and encoding 
(P<0.005) 
Lewerin, 
2005 [49] 
Males and females 
Mean age: 76y 
Community-dwelling 
 
179 Vitamin tablet 
(0.5mg vitamin B-
12, 0.8mg folic acid 
and 3mg vitamin B-
6)/d vs placebo 
(Vitamin tablet 
provided to 64% of 
participants) 
4 months Cognitive testing at baseline and after 
treatment. 
Tests included: digit span forward, digit 
span backward, identical forms, visual 
reproduction, synonyms, block design, 
digit symbol 90s, Thurstone’s Picture 
Memory test and figure classification 
Cognitive test scores improved for both 
arms and were only different between 
placebo and vitamin arms for identical 
forms (P: 0.039) and synonyms (P: 
0.017) tests, both of which had greater 
improvement in the placebo arm. 
McMahon, 
2006 [50] 
Males and females 
≥ 65y (mean: 74) 
Community-dwelling 
No suspected dementia 
No medications that 
interfere with folate 
metabolism 
No B-vitamin 
supplementation 
Fasting homocysteine  
≥ 13µmol/l 
Normal plasma 
creatinine (≤ 133µmol/l 
253 Vitamin tablet (1mg 
folate, 0.5mg 
vitamin B-12 and 
10mg of vitamin B-
6)/d vs placebo 
2 years Cognitive function assessed at baseline, 
1 year and 2 years.  
Global cognitive function assessed by 
MMSE. 
Other tests included: memory and 
learning capacity, paragraph-recall, 
learning and recall ability, verbal 
fluency, semantic fluency, information-
processing speed and reasoning ability. 
Combined treatment score for all 8 
tests was poorer in vitamin compared 
to placebo group (-0.11 SD scores 
poorer; 95% CI: -0.22, 0.00; P: 0.05). 
Significant difference between trial 
arms only observed for paragraph 
recall test (mean difference: -1.19; 
95%CI: -2.30, -0.04; P: 0.03, but no 
longer significant if adjusted for sex 
and education) and retain trail marking 
test, part B (mean difference: -7%; 
95% CI: -13, -2; P: 0.009) with both 
poorer in vitamin group. 
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in men;  
≤ 115µmol/l in women) 
Obeid, 
2005 [51] 
Males and females 
Mean age: 81y 
Glomerular filtration 
rate >30ml/min 
MMSE score >15 
69 Daily subcutaneous 
injection: vitamin 
(1mg vitamin B-12, 
5mg vitamin B-6 
and 1.1mg folate)/d 
vs placebo for 3 
weeks followed by 
daily tablet 
ingestion (same 
composition) for 3 
weeks. 
45 days Cognitive function assessed at baseline 
and after treatment.  
Function assessed by MMSE and 
Structured Interview for Diagnosis of 
Dementia of Alzheimer Type, Multi-
infarct Dementia and Dementia 
No treatment effects reported, only 
within-group difference in performance 
Sommer, 
2003 [52] 
Males and females 
≥ 65y (mean: 76.7) 
Community-dwelling 
With dementia 
(diagnosed by DSM-III) 
Serum folate 2-5µg/l 
Red blood cell folic acid 
127-452µg/l 
Normal vitamin B-12 
(>200ng/l) 
 
7 Folic acid (10mg) 
vs placebo twice 
daily 
10 
weeks 
Cognitive function assessed at baseline 
and after treatment. 
Tests included: MMSE and a test 
battery assessing: intellectual function, 
confrontation naming, verbal fluency, 
verbal memory, visuospatial memory, 
visual scanning, conceptual flexibility 
and motor speed.  
No difference in change in test scores 
between folic acid and placebo groups.  
Trend for folic acid to reduce 
performance on the associate learning 
subtests (P: 0.08) (a measure of short-
term verbal memory) and Trail B 
marking test (P: 0.08) (a measure of 
speed and concentration).  
Stott, 
2005 [53] 
Males and females 
≥ 65y (mean: 75) 
Hospital-based 
167 2 x 2 x 2 factorial 
design:  
a. folic acid 
12 
weeks 
Cognitive function assessed at baseline, 
and 12 months after randomization.  
General cognitive function assessed by 
No effect on change in cognitive 
function  
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with ischemic vascular 
disease2
MMSE score ≥ 19 
No B-vitamin treatment 
Normal folate (red 
blood cell folate ≥ 
280ng/ml) 
Normal vitamin B-12  
(≥ 250pg/ml) 
(2.5mg) + 
vitamin B-12 
(0.5mg) vs 
placebo 
b. vitamin B-6 
(25mg) vs 
placebo 
c. riboflavin 
(25mg) vs 
placebo. 
TICSm. 
Face-to-face interviews also assessed 
attention and speed of information 
processing 
VITAL, 
2003 [54] 
Males and females 
Community-dwelling 
Dementia (diagnosed 
by DSM-IV) and MMSE 
score 12-26 or TICSm 
score <27 
128 2 x 2 x 2 factorial 
design:  
a. aspirin (81mg) 
vs placebo 
b. folic acid (2mg) 
+ vitamin B-12 
(1mg) vs 
placebo 
c. vitamin-E 
(500mg) + 
vitamin-C 
(200mg) vs 
placebo  
12 
weeks 
Cognitive function assessed at 
randomization and after treatment.  
Cognitive function assessed by MMSE 
and ADAS-Cog 
No effect of treatment on cognitive 
function  
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ADAS-Cog = cognitive part of Alzheimer’s Disease Assessment Scale [98]; DSM-III/IV= Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition [93]/ 4th 
Edition [22]; MMSE = Mini-Mental State Examination [94]; TICSm = Telephone Interview for Cognitive Status 
1All are randomized double-blind, placebo-controlled trials  
2Ischemic vascular disease defined as one or more of: history of angina pectoris, previous acute myocardial infarction, evidence of major ischemia or previous acute 
myocardial infarction on the basis of a 12-lead electrocardiogram, ischemic stroke, transient ischemic attack, intermittent claudication or surgery for peripheral 
arterial disease. 
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Table 3. Summary of cohort studies included in analysis relating fish, DHA, EPA, n-3 PUFAs intake to risk of incident AD and dementia 
First 
author, 
year 
Study population N 
(loss to 
follow-up) 
Duration 
(mean 
follow-
up) 
Exposure Cognitive 
measure 
Statistical 
analysis 
Outcomes / major results 
Barberger-
Gateau, 
2002 [42]1
Males and females 
≥ 68 
Community-dwelling 
Free from dementia 
at baseline 
1674 
(15.4%: 
variables 
associated 
with loss to 
follow-up 
not 
reported) 
7 years Fish or 
seafood 
consumption 
assessed by 
FFQ 
MMSE score 
and diagnosis 
of dementia 
based on 
criteria from 
DSM-III (AD 
diagnosis 
criteria not-
specified) 
Cox proportional 
hazards model 
comparing risk of 
dementia according 
to fish or seafood 
consumption group 
(once a day/at least 
once a week (but 
not every day)/from 
time to time (but not 
weekly)/never 
(reference group)) 
Adjusted for age, 
sex and education 
170 cases of incident dementia (of which 
135 were AD). 
Marginal association between 
consumption of fish or seafood at least 
once a week and a reduced risk of 
dementia and AD (adjusted HR for all 
cause dementia: 0.73; 95% CI: 0.52, 
1.03; adjusted HR for AD: 0.69; 95% CI: 
0.47, 1.01). 
Engelhart, 
2002 [39]1
Males and females 
≥ 55y (mean: 68) 
Community-dwelling 
Free from dementia 
at baseline 
 
5395 
(16%: more 
likely to be 
older, 
males and 
to have 
less 
education) 
6y  
(SD: 1.3) 
Intake of n-3 
PUFAs 
assessed by 
semi-
quantitative 
FFQ 
Screened 
using MMSE 
and clinical 
examination 
Dementia 
diagnosis 
based on 
criteria from 
Cox proportional 
hazards model 
comparing risk of 
dementia or AD in 
relation to standard 
deviation of fat 
intake (linear 
variable) 
197 cases of incident dementia (of which 
146 were AD). 
No association between n-3 PUFA intake 
and dementia or AD (adjusted HR for all 
cause dementia: 1.07; 95% CI: 0.94, 
1.22; adjusted HR for AD: 1.07; 95% CI: 
0.91, 1.25) 
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DSM-III. AD 
diagnosis 
based on 
criteria from 
NINCDS-
ADRDA. 
 
Energy-adjusted 
intake  
Adjusted for age, 
sex, education, 
intake of vitamin E 
and total energy 
intake 
Huang, 
2005 [43]3
Males and females 
≥ 65y 
Community-dwelling 
Free from dementia 
or MCI at baseline 
2233 
(23.4%: 
variables 
associated 
with loss to 
follow-up 
not 
reported) 
5.4y Fish intake 
assessed by 
semi-
quantitative 
FFQ 
Dementia 
diagnosed 
according to 
criteria of 
DSM-IV. AD 
diagnosis 
based on 
criteria from 
NINCDS-
ADRDA 
Cox proportional 
hazards model 
comparing risk of 
dementia for group 
of fish (fried fish or 
tuna and other fish) 
intake. Fried fish 
intake grouped into 
three categories 
(<0.25 servings/wk: 
reference), tuna 
and other fish 
grouped into four 
categories (<0.25 
servings/wk: 
reference) 
Adjusted for age, 
minority status, sex, 
APOE-ε4, total 
energy intake, BMI, 
378 cases of incident dementia (of which 
190 were AD). 
No association between fried fish 
consumption and risk of dementia or AD 
(highest intake (≥ 2 servings/wk) 
adjusted HR for all cause dementia: 0.97; 
95% CI: 0.69, 1.35; adjusted HR for AD: 
0.95; 95% CI: 0.60, 1.52). 
Despite a univariate association, in fully-
adjusted models there was no 
association between tuna and other fish 
consumption and risk of dementia or AD 
(highest intake (≥ 4 servings/wk) 
adjusted HR for all cause dementia: 0.79; 
95% CI: 0.53, 1.20; adjusted HR for AD: 
0.69; 95% CI: 0.91, 1.22)  
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region, education 
and income. 
Laitinen, 
2006 [44]4
Males and females 
Mean age at 
baseline: 50.4y (SD: 
6.0) 
Community-dwelling 
Free from dementia 
at baseline 
1449 
(27.5: 
variables 
associated 
with loss to 
follow-up 
not 
reported) 
21y 
(SD: 4.9) 
PUFA intake 
from spreads 
derived from 
self-
administered 
questionnaire 
with short 
quantitative 
section on 
spreads used 
on bread 
Screening via 
MMSE and 
dementia 
diagnosis with 
criteria of 
DSM-IV. AD 
diagnosis 
based on 
criteria from 
NINCDS-
ADRDA.  
Logistic regression 
models comparing 
odds of dementia 
and AD for quartiles 
of PUFA intake 
(lowest quartile: 
reference). 
Adjusted for: age, 
sex, education, 
follow-up time,  
APOE-ε4, other fat 
intake, baseline 
systolic BP, BMI, 
cholesterol, 
smoking, history of 
myocardial 
infarction, stroke 
and diabetes. 
117 incident cases of dementia (of which 
76 were AD). 
Moderate PUFA intake was associated 
with decreased risk of dementia but not 
AD (second quartile (0.5-0.8g) vs first 
quartile (<0.5g) adjusted OR for all cause 
dementia: 0.4; 95% CI: 0.17, 0.94; 
adjusted OR for AD: 0.53; 95% CI: 0.21, 
1.37). No association between higher 
intakes and risk of dementia or AD. 
Laurin, 
2003 [38]5
Males and females 
≥ 65y (mean: 76.9) 
Community and 
institutional-dwelling 
Free from dementia 
at baseline 
Participants chosen 
79 
(81.4%: 
variables 
associated 
with loss to 
follow-up 
from the 
5 years Serum 
concentrations 
of EPA, DHA 
and n-3 PUFA  
Screening via 
MMSE, CIND 
according to 
modified 
Zaudig’s 
criteria [99] 
and dementia 
t-test comparing 
fatty acid 
concentration 
between individuals 
developing CIND or 
dementia and those 
without.  
16 cases of incident CIND and 11 cases 
of dementia.  
Individuals with CIND had 31% higher 
mean relative concentration of EPA (P: 
0.01) compared to unimpaired 
individuals.  
Individuals with all cause dementia had 
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from large national 
cohort of which only 
4% provided blood 
sample 
 
425 
individuals 
with blood 
samples 
not 
reported) 
diagnosis with 
criteria of 
DSM-IV.  
Adjusted for: age, 
sex, education, 
smoking, alcohol 
intake, BMI, history 
of cardiovascular 
disease and  
APOE-ε4. 
30% higher mean relative concentrations 
of DHA (P: 0.07), and 21% higher n-3 
PUFAs (P: 0.04) than unimpaired 
individuals 
There were no other differences relating 
to EPA, DHA or n-3 PUFAs.  
Morris, 
2003 [40]6  
Males and females 
≥ 65y 
Community-dwelling 
Free from dementia 
or with mild cognitive 
impairment at 
baseline 
815 
(35%: 
variables 
associated 
with loss to 
follow-up 
not 
reported) 
3.9y Fish, total n-3 
fatty acid, DHA 
and EPA 
intake 
assessed by 
self-
administered 
FFQ 
AD diagnosis 
based on 
criteria of 
NINCDS-
ADRDA 
(demented 
cases without 
AD were 
analyzed as 
non-cases) 
Logistic regression 
models comparing 
odds of AD with 
quintiles of energy-
adjusted n-3 fatty 
acid intake (first 
quintile: reference).  
Logistic regression 
models comparing 
frequency of fish 
consumption with 
risk of AD (never: 
reference). 
Adjusted for: age, 
sex, education, 
APOE-ε4, race x 
APOE-ε4 
interaction, period 
of observation. 
 
131 cases of incident AD. 
Higher intake of total n-3 fatty acids was 
associated with reduced risk of AD 
(highest quintile (median: 1.75g/d) vs 
lowest quintile (0.9g/d) adjusted RR: 0.4; 
95% CI: 0.1, 0.9). 
Higher intake of DHA associated with 
reduced risk of AD (highest quintile 
(median: 0.1g/d) vs lowest quintile 
(median: 0.03g/d) adjusted RR: 0.3; 95% 
CI: 0.1, 0.9). 
No association between EPA intake and 
risk of AD (highest quintile (median: 
0.03g/d) vs lowest quintile (0.0g/d) 
adjusted RR: 0.9; 95% CI: 0.4, 2.3). 
Frequent fish consumption associated 
with reduced risk of AD (highest 
frequency (≥ 2/wk) vs never adjusted RR: 
0.4; 95% CI: 0.2, 0.9) 
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Schaefer, 
2006 [41]7
Males and females 
≥ 55y 
Community-dwelling 
Free from dementia 
at baseline 
 
488 
(75%: more 
likely to be 
older; other 
variables 
associated 
with loss to 
follow-up 
not 
reported) 
9.1y Plasma DHA 
and EPA.  
Dietary fish 
and DHA 
intake also 
assessed by 
self-
administered 
semi-
quantitative 
FFQ. 
 
Dementia 
diagnosis 
based on 
criteria of 
DSM-IV as 
well as a 
duration of 
symptoms >6 
months and a 
score of ≥ 1 of 
severity on the 
Clinical 
Dementia 
Rating scale. 
AD defined 
based on 
criteria from 
NINCDS-
ADRDA. 
Cox proportional 
hazards models 
comparing risk of 
dementia with 
quartiles of plasma 
DHA (quartiles 1-3: 
reference).  
Similar analysis 
was conducted for 
baseline DHA and 
fish intakes. 
Adjusted for: age, 
sex, APOE-ε4, 
homocysteine 
concentration, 
education 
 
99 cases of incident dementia (of which 
71 were AD).  
Highest DHA concentration associated 
with reduced risk of all cause dementia 
(highest quartile (>4.2%) vs quartiles 1-3 
combined adjusted RR: 0.53; 95% CI: 
0.29, 0.97).  
No association between DHA 
concentration and risk of AD (adjusted 
RR: 0.61; 95% CI: 0.31, 1.18). 
No association between plasma levels of 
EPA and risk of dementia or AD (data not 
shown). 
No association between dietary DHA or 
fish consumption with dementia or AD.  
Solfrizzi, 
2006 [37]8
Males and females 
≥ 65y (mean: 73) 
Community and 
institutional-dwelling 
278 
(61%: more 
likely to be 
older and 
with less 
education) 
622 
person-
years 
Dietary intake 
of PUFA 
assessed by 
semi-
quantitative 
FFQ 
MCI assessed 
by MMSE 
score, memory 
status (BSRT) 
and functional 
capacity 
(ADL). MCI 
defined as 
Proportional hazard 
models comparing 
risk of MCI by 
quartile of PUFA 
intake. 
Adjusted for: age, 
education and total 
energy intake 
18 cases of incident MCI. 
No association between PUFA intake 
and risk of MCI in adjusted analysis, 
(highest quartile (≥ 9g/d) vs lowest 
quartile (≤ 5g/d) adjusted HR: 0.62; 95% 
CI: 0.34, 1.13).  
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MMSE 
adjusted score 
<1.5SD from 
the mean age- 
and education 
adjusted 
MMSE score 
for non-
demented 
individuals. 
Total BRST 
score in lowest 
10th percentile 
and disabilities 
compromising 
ADL 
95% CI = 95% Confidence Interval; AD = Alzheimer’s Disease; ADL = Activities of Daily Living scale [100]; BMI = Body Mass Index; BP = Blood Pressure; BSRT = 
Babcock Story Recall Test [101]; CIND = Cognitively Impaired but Not Demented; DHA = Docosahexaenoic Acid; DSM-III/IV= Diagnostic and Statistical Manual of 
Mental Disorders, 3rd Edition [93]/ 4th Edition [22]; EPA = Eicosapentaenoic Acid; FFQ = Food Frequency Questionnaire; HR = Hazard Ratio; MCI = Mild Cognitive 
Impairment; MMSE = Mini-Mental State Evaluation [94]; NINCDS-ADRDA = National Institute of Neurological and Communicative Disorders and Stroke – 
Alzheimer’s Disease and Related Disorders Association [23]; PUFA = Polyunsaturated Fatty Acids; SD = Standard Deviation 
1Personnes Agees QUID study (PAQUID); 2The Rotterdam Study; 3Cardiovascular Health Cognition Study (CHCS); 4Cardiovascular risk factors, Aging and 
Incidence of Dementia study (CAIDE); 5Canadian Study of Health and Aging (CSHA); 6Chicago Health and Aging Project (CHAP); 7The Framingham Heart Study; 
8The Italian Longitudinal Study on Aging (ILSA); 
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Table 4. Summary of RCTs examining fatty acid intervention on cognitive function. 
First 
author, 
year 
Study population N Intervention1 Duration Cognitive measure Outcome / main results 
Freund-
Levi, 2006 
[55] 
Males and females 
Mean age: 74y 
With AD according to 
DSM-IV criteria 
MMSE score 15-30 
Living in own home 
Receiving treatment 
with acetylcholine 
esterase inhibitors 
174 4 tablets daily 
containing: 430mg 
DHA + 150mg EPA 
vs placebo  
Intervention for 6 
months followed by 
open treatment with 
n-3 supplements 
for all participants 
for further 6 months 
12 
months 
Cognitive function assessed at 
baseline, 6 and 12 months by MMSE 
and ADAS-COG 
MMSE declined and ADAS-COG 
increased from baseline to 6 and 12 
months in both groups but with no 
significant difference between treatment 
groups (values not reported).  
 
Jorissen, 
2001 [57] 
Males and females 
>57y 
Community-dwelling 
With mild to moderate 
cognitive deterioration 
as assessed by AAMI 
MMSE score >24 
120 Three trial arms: 
a. 300mg Soya 
bean 
Phosphatidyl-
serine (S-PS) 
b. 600mg S-PS 
c. Placebo 
(S-PS contains 
28% PUFA) 
12 
weeks 
Cognitive function assessed by battery 
of neuropsychological tests at 
baseline, 6 weeks and 12 weeks.  
Tests included: visual verbal learning, 
memory scanning, verbal fluency, 
Stroop color word, signal detection, 
motor choice reaction time, concept 
shifting and tower of London test.  
No effect of treatment on primary 
outcome of long-term memory 
performance (assessed by visual verbal 
learning test).  
No treatment effects on secondary 
cognitive outcomes.  
Terano, Males and females 20 Intervention group: 1 year Cognitive function assessed at HDS-R and MMSE scores improved in 
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1999 [56]2 Mean age: 83y 
Institutional-dwelling 
MMSE score 15-22 
HDS-R score 15-22 
0.72g DHA/d  
Control group: 
nothing  
baseline, 3, 6 and 12 months.  
Cognitive function assessed by 
MMSE, HDS-R and clinical evaluation  
the supplementation group whereas the 
control group remained unchanged. 
However, treatment effect statistics not 
reported. 
Yehuda, 
1996 [58] 
Males and females 
50-73y 
Community-dwelling 
Complaints of 
disorientation and 
cognitive deficit 
Low score on MMSE 
(mean sample score: 
7.8) 
No multi-infarction 
dementia, post-
depressive dementia or 
post-traumatic 
dementia 
100 Fatty acid 
preparation (n-3: n-
6 ratio of 1:4) 
known as SR-3 
provided as 2ml/d 
vs placebo 
4 weeks Cognitive function assessed by a 12 
item questionnaire completed by 
patient’s guardian or care-giver and 
rating (5-point scale) various aspects 
of quality of life. Questionnaire 
assessed at baseline and after 
treatment.  
Components: space orientation, 
cooperation, mood, appetite, 
organization, short-term memory, long-
term memory, sleep problems, daytime 
alertness, hallucinations, self-
expression and bladder control 
Greater improvement in intervention arm 
compared to placebo for all of the 
components of quality of life 
questionnaire with the exception of 
bladder control (statistical analysis of 
treatment effect not reported).  
AAMI = Age-Associated Memory Impairment; AD = Alzheimer’s Disease; ADAS-COG = Alzheimer Disease Assessment Scale [98]; DHA = Docosahexaenoic Acid; 
DSM-III/IV= Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition [93]/ 4th Edition [22]; EPA = Eicosapentaenoic Acid; HDS-R = Hasegawa’s Dementia 
rating scale; MMSE = Mini-Mental State Evaluation [94]; PUFA = Polyunsaturated Fatty Acids 
1All studies are randomized double-blind, placebo-controlled trials unless stated otherwise  
2This trial was not double-blind and the control group did not receive a placebo 
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Figure 1. Flow chart of included and excluded papers in the literature search. 
 
Footnote: 
1Details of excluded studies from step 2 are in web appendix 2 
2A number of cohort studies included relevant data on folate, other B-vitamins and 
homocysteine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
